drugset / Trial / NCT06961721
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
Phase 4
Not yet recruiting
600 enrolled
Changchun BCHT Biotechnology Co.
Center for Disease Control and Prevention, Fujian · collabInner Mongolia Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.
Timeline
- Start
- 2025-05
- Primary completion
- 2025-07
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Herpes Zoster Vaccine, Live | Vaccine | 0.5 ml | — |